Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson et al.
Nature Communications
Papers
September 2018
Authors and Affiliates
K.G. Paulson1,2,3, V. Voillet2, M.S. McAfee2, D.S. Hunter2, F.D. Wagener2, M. Perdicchio2,6, W.J. Valente2, S.J. Koelle1,2, C.D. Church1, N. Vandeven1, H. Thomas1, A.G. Colunga1, J.G. Iyer1, C. Yee4, R. Kulikauskas1, D.M. Koelle1,2,5, R.H. Pierce2, J.H. Bielas1,2, P.D. Greenberg1,2, S. Bhatia1,2,3, R. Gottardo1,2, P. Nghiem1,2,3 & A.G. Chapuis1,2,3
1University of Washington, Seattle, WA, USA. 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3Seattle Cancer Care Alliance, Seattle, WA, USA. 4MD Anderson Cancer Center, Houston, TX, USA. 5Benaroya Research Institute, Seattle, WA, USA.